Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
